Global Payments (GPN) Gets a Buy Rating from Oppenheimer

In a report released yesterday, Glenn Greene from Oppenheimer maintained a Buy rating on Global Payments (GPN – Research Report), with a price target of $180.00. The company’s shares closed last Tuesday More »

Momenta Pharma (MNTA) Gets a Buy Rating from Stifel Nicolaus

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Momenta Pharma (MNTA – Research Report). The company’s shares closed last Tuesday at $26.49. According to TipRanks.com, More »